Cargando…

Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma

Patients with advanced melanoma that is resistant to PD-1 blockade therapy have limited treatment options. Vidutolimod (formerly CMP-001), a virus-like particle containing a CpG-A Toll-like receptor 9 (TLR9) agonist, may reverse PD-1 blockade resistance by triggering a strong IFN response to induce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ribas, Antoni, Medina, Theresa, Kirkwood, John M., Zakharia, Yousef, Gonzalez, Rene, Davar, Diwakar, Chmielowski, Bartosz, Campbell, Katie M., Bao, Riyue, Kelley, Heather, Morris, Aaron, Mauro, David, Wooldridge, James E., Luke, Jason J., Weiner, George J., Krieg, Arthur M., Milhem, Mohammed M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2021
Materias:	Research Brief
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799774/ https://www.ncbi.nlm.nih.gov/pubmed/34326162 http://dx.doi.org/10.1158/2159-8290.CD-21-0425

Ejemplares similares

Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade–Resistant Advanced NSCLC
por: Negrao, Marcelo V., et al.
Publicado: (2022)

Monocytes Exposed to Immune Complexes Reduce pDC Type 1 Interferon Response to Vidutolimod
por: Sabree, Shakoora A., et al.
Publicado: (2021)

PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV
por: Davar, Diwakar, et al.
Publicado: (2015)

Toll-Like Receptor 9 Agonists in Cancer
por: Karapetyan, Lilit, et al.
Publicado: (2020)

Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma
por: Swami, Umang, et al.
Publicado: (2019)

Adjuvant Therapy: Melanoma
por: Davar, Diwakar, et al.
Publicado: (2011)

Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events
por: Swami, Umang, et al.
Publicado: (2019)

Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review
por: Greco, Austin, et al.
Publicado: (2019)

Current status of intralesional agents in treatment of malignant melanoma
por: Zawit, Misam, et al.
Publicado: (2021)

Pembrolizumab Therapy Triggering an Exacerbation of Preexisting Autoimmune Disease: A Report of 2 Patient Cases
por: Phadke, Sneha D., et al.
Publicado: (2016)

Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma
por: Comin-Anduix, Begoña, et al.
Publicado: (2010)

Multivariable Analysis of 169 Cases of Advanced Cutaneous Melanoma to Evaluate Antibiotic Exposure as Predictor of Survival to Anti-PD-1 Based Immunotherapies
por: Swami, Umang, et al.
Publicado: (2020)

Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial
por: Ellingsen, Espen B., et al.
Publicado: (2023)

Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
por: Chmielowski, Bartosz
Publicado: (2013)

Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy
por: Davar, Diwakar, et al.
Publicado: (2022)

Toll-like receptor 9 interaction with CpG ODN – An in silico analysis approach
por: Zhou, Wei, et al.
Publicado: (2013)

Immunostimulatory Activities of CpG-Oligodeoxynucleotides in Teleosts: Toll-Like Receptors 9 and 21
por: Lai, Chao-Yang, et al.
Publicado: (2019)

High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute
por: Davar, Diwakar, et al.
Publicado: (2017)

Synthetic Hexanucleotides as a Tool to Overcome Excessive Neutrophil Activation Caused by CpG-Containing Oligonucleotides
por: Golenkina, Ekaterina A., et al.
Publicado: (2021)

Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma
por: Augustin, Ryan C, et al.
Publicado: (2023)

Tumor cell p38 inhibition to overcome immunotherapy resistance
por: Luke, Jason J., et al.
Publicado: (2023)

Overcoming Aging-Associated Poor Influenza Vaccine Responses with CpG 1018 Adjuvant
por: Kang, Xinliang, et al.
Publicado: (2022)

CpG oligonucleotide activates Toll-like receptor 9 and causes lung inflammation in vivo
por: Knuefermann, Pascal, et al.
Publicado: (2007)

Single Molecule In Vivo Analysis of Toll-Like Receptor 9 and CpG DNA Interaction
por: Chen, Jiji, et al.
Publicado: (2011)

The Toll-like receptor ligand, CpG oligodeoxynucleotides, regulate proliferation and osteogenic differentiation of osteoblast
por: Yu, Wenwen, et al.
Publicado: (2020)

CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity
por: Chu, Rose S., et al.
Publicado: (1997)

Regulation of innate and adaptive immunity and autoimmunity by Toll-like receptor 9
por: Krieg, AM
Publicado: (2004)

Epigenetic modulation in sensitizing metastatic sarcomas to therapies and overcoming resistance
por: Rytlewski, Jeff, et al.
Publicado: (2022)

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
por: Shaikh, Saba S., et al.
Publicado: (2022)

Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers
por: Cooper, Curtis L, et al.
Publicado: (2008)

Nuclease-resistant immunostimulatory phosphodiester CpG oligodeoxynucleotides as human Toll-like receptor 9 agonists
por: Meng, Wenjun, et al.
Publicado: (2011)

Equilibrium Binding Model for CpG DNA-Dependent Dimerization of Toll-like Receptor 9 Ectodomain
por: Reikine, Stephanie, et al.
Publicado: (2020)

Correction: The Toll-like receptor ligand, CpG oligodeoxynucleotides, regulate proliferation and osteogenic differentiation of osteoblast
por: Yu, Wenwen, et al.
Publicado: (2023)

MEK inhibitors for the treatment of NRAS mutant melanoma
por: Sarkisian, Saro, et al.
Publicado: (2018)

Targeting GITR in cancer immunotherapy – there is no perfect knowledge
por: Davar, Diwakar, et al.
Publicado: (2023)

Selenium targets resistance biomarkers enhancing efficacy while reducing toxicity of anti-cancer drugs: preclinical and clinical development
por: Zakharia, Yousef, et al.
Publicado: (2018)

Melanoma Brain Metastases in the Era of Targeted Therapy and Checkpoint Inhibitor Therapy
por: Rieth, John M., et al.
Publicado: (2021)

CRAF R391W is a melanoma driver oncogene
por: Atefi, Mohammad, et al.
Publicado: (2016)

Phosphodiester backbone of the CpG motif within immunostimulatory oligodeoxynucleotides augments activation of Toll-like receptor 9
por: Pohar, Jelka, et al.
Publicado: (2017)

A retrospective analysis of the impact of the COVID-19 pandemic on staging at presentation of patients with invasive melanoma
por: Shaikh, Saba S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kl8rm96j27277imr5lo2o3flul